Pfizer, Bristol-Myers: Anticlotting drug met goals
Thursday, June 23, 2011
NEW YORK (AP) — Drugmakers Pfizer Inc. and Bristol-Myers Squibb Co. say their experimental anticlotting drug, for preventing strokes, met goals of a large, late-stage study comparing it to an older drug, Coumadin.
Patients getting the new drug, called Eliquis, had no more strokes or dangerous clots than those getting Coumadin, also called warfarin. Eliquis, known chemically as apixaban, caused less major internal bleeding than warfarin, the companies said.
The companies, both based in New York, are partnering to develop Eliquis, a new type of anticlotting pill.
They plan to present detailed results from the 18,201-patient international study, called ARISTOTLE, at a Paris medical conference in August and to apply by year’s end for U.S. and European regulatory approval.
Use the comment form below to begin a discussion about this content.
Please review our Policies and Procedures before registering or commenting